Tag: RemeGen
New Data Demonstrates Potential for RemeGen’s RC48 in HER2+ Cancers
Results from a robust oncology pipeline, including the latest phase II data of an investigational antibody-drug conjugates (ADC) called RC48 being developed by RemeGen...
Researchers Develop Novel anti-CD19 Antibody-drug Conjugates for the Treatment of B-cell...
In an article published in July 2018 edition of the International Immunopharmacology researchers and scientists from RemeGen (Yantai 264006, Shandong, China) and Mabplex International...
